Difference between revisions of "Template:Article of the week"

From LIMSWiki
Jump to navigationJump to search
(Updated article of the week text)
(23 intermediate revisions by the same user not shown)
Line 1: Line 1:
<div style="float: left; margin: 0.5em 0.9em 0.4em 0em;">[[File:Fig1 Baratta FrontPharmaco2019 10.jpg|240px]]</div>
<div style="float: left; margin: 0.5em 0.9em 0.4em 0em;">[[File:Anx1 WHO 2020 2020.5.png|240px]]</div>
'''"[[Journal:Development of standard operating protocols for the optimization of Cannabis-based formulations for medical purposes|Development of standard operating protocols for the optimization of Cannabis-based formulations for medical purposes]]"'''
'''"[[Journal:Laboratory testing for coronavirus disease (COVID-19) in suspected human cases|Laboratory testing for coronavirus disease (COVID-19) in suspected human cases]]"'''


Under current legislation in Italy, using the ''[[wikipedia:Cannabis|Cannabis]]'' plant for medical purposes requires administering it orally in the form of a decoction or as ''Cannabis'' oil extract. The scientific literature reports a number of preparation methods, mainly for oils, but no study is available that compares thoroughly, from a technological viewpoint, the ''Cannabis''-based formulations currently administered to patients. With this in mind, this research work aimed to carry out specific formulation studies to design standard operating procedures for the preparation and optimization of ''Cannabis''-based galenic formulations. Both decoctions and oils were prepared under different operating conditions to identify the most efficient process for the production of formulations with a high concentration of [[wikipedia:Decarboxylation|decarboxylated]] [[wikipedia:Tetrahydrocannabinol|delta-9-tetrahydrocannabinol]] (THC) and [[wikipedia:Cannabidiol|cannabidiol]] (CBD). Regarding ''Cannabis'' oil, a new procedure has been developed that allows significantly higher recovery rates for THC and CBD compared with those for water-based extraction methods (decoction) and those for oil-based methods currently in use. ('''[[Journal:Development of standard operating protocols for the optimization of Cannabis-based formulations for medical purposes|Full article...]]''')<br />
This document provides interim guidance to [[Laboratory|laboratories]] and stakeholders involved in [[COVID-19]] virus laboratory testing of patients. It is based in part on the interim guidance on laboratory testing for [[Middle East respiratory syndrome]] (MERS) coronavirus. [[Information]] on human [[infection]] with the COVID-19 virus is evolving and the [[World Health Organization]] (WHO) continues to monitor developments and revise recommendations as necessary. This document will be revised as new information becomes available. Feedback is welcome and can be sent to WHElab@who.int. The virus has now been named SARS-CoV-2 by the International Committee of Taxonomy of Viruses (ICTV)(2). This virus can cause the disease named coronavirus disease 2019 (COVID-19). WHO refers to the virus as COVID-19 virus in its current documentation. ('''[[Journal:A security review of local government using NIST CSF: A case study|Full article...]]''')<br />
<br />
<br />
''Recently featured'':
''Recently featured'':
: ▪ [[Journal:Next steps for access to safe, secure DNA synthesis|Next steps for access to safe, secure DNA synthesis]]
: ▪ [[Journal:One tool to find them all: A case of data integration and querying in a distributed LIMS platform|One tool to find them all: A case of data integration and querying in a distributed LIMS platform]]
: ▪ [[Journal:Japan Aerospace Exploration Agency’s public-health monitoring and analysis platform: A satellite-derived environmental information system supporting epidemiological study|Japan Aerospace Exploration Agency’s public-health monitoring and analysis platform: A satellite-derived environmental information system supporting epidemiological study]]
: ▪ [[Journal:What is the "source" of open-source hardware?|What is the "source" of open-source hardware?]]
: ▪ [[Journal:Smart grids and ethics: A case study|Smart grids and ethics: A case study]]
: ▪ [[Journal:From command-line bioinformatics to bioGUI|From command-line bioinformatics to bioGUI]]

Revision as of 15:46, 23 March 2020

Anx1 WHO 2020 2020.5.png

"Laboratory testing for coronavirus disease (COVID-19) in suspected human cases"

This document provides interim guidance to laboratories and stakeholders involved in COVID-19 virus laboratory testing of patients. It is based in part on the interim guidance on laboratory testing for Middle East respiratory syndrome (MERS) coronavirus. Information on human infection with the COVID-19 virus is evolving and the World Health Organization (WHO) continues to monitor developments and revise recommendations as necessary. This document will be revised as new information becomes available. Feedback is welcome and can be sent to WHElab@who.int. The virus has now been named SARS-CoV-2 by the International Committee of Taxonomy of Viruses (ICTV)(2). This virus can cause the disease named coronavirus disease 2019 (COVID-19). WHO refers to the virus as COVID-19 virus in its current documentation. (Full article...)

Recently featured:

▪ One tool to find them all: A case of data integration and querying in a distributed LIMS platform
▪ What is the "source" of open-source hardware?
▪ From command-line bioinformatics to bioGUI
Retrieved from "https://www.limswiki.org/index.php?title=Template:Article_of_the_week&oldid=38742"